There has been tremendous progress in advancing gene therapies and delivering these life-changing medicines to patients worldwide. However, with these advancements come new challenges, from manufacturing bottlenecks to safe therapeutic vectors. As we enter a new era of gene therapy innovation, how are the next generation of genetic medicines addressing these concerns? Hear from a diverse panel of experts as they discuss novel approaches in development that have the potential to solve some of the greatest problems facing the field, including building manufacturing infrastructure with capacity to provide broader access to these medicines, utilizing novel non-viral vectors and innovation in vector engineering, improving cost efficiency, broadening the application of gene therapy to other hard-to-treat rare diseases but also to broad indications that impact millions of people worldwide.
